CAR-T Cell Therapy for Leukemia from China
CAR-T cell therapy consists of patient-derived T-cells that are genetically modified to express chimeric antigen receptors targeting CD19-positive cancer cells. These engineered cells are used for the treatment of relapsed B-cell acute lymphoblastic leukemia and are classified as cell therapy products under tariff item 3002.51.00.
Duty Rate — China → Canada
Import Tips
• Ensure the product is accompanied by a valid Health Canada authorization or clinical trial approval, as cell therapy products are regulated under the Food and Drugs Act
• Provide detailed documentation on the genetic modification process and cell viability to support classification under 3002.51.00
• Coordinate with the CBSA and the Canadian Food Inspection Agency (CFIA) if the product contains animal-derived components